DIABETIC NEPHROPATHY AN OBVIOUS COMPLICATION IN LONG TERM TYPE 1 DIABETES MELLITUS: A CASE STUDY

Authors

  • Jahidul Islam Mohammad Department of Pharmacology, Faculty of Medicine, Cyberjaya University College of Medical Sciences, CUCMS, Cyberjaya, 63000, Malaysia.
  • Sridevi Chigurupati Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah, Malaysia.
  • Azli Shahril Othman Department of Pharmacology, Faculty of Medicine, Cyberjaya University College of Medical Sciences, CUCMS, Cyberjaya, 63000, Malaysia.
  • Muhammad Zahid Iqbal Department of Clinical Pharmacy, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah, Malaysia.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i11.20699

Keywords:

Type 1 diabetesmellitus, Albuminuria, Diabetic nephropathy

Abstract

 

 Most overwhelming complications of Type 1 diabetes mellitus patients are responsible for complications related to the microvascular system most likely with kidney. In the kidney, hyperglycemia induced microangiopathy resulting not only thickening of the glomerular capillary basement membrane but also to the proliferation of the mesangial matrix and solidifying of the tubular basement membrane. Several biochemical and pathological, factors are concerned for the development of diabetic renal microangiopathy. These include the glomerular hyperperfusion and hyperfiltration, transformed morphology of podocytes accompanies these basement membrane modifications, Type IV collagen augmented synthesis following the hyperglycemia, and increased expression of tissue matrix metalloproteinase. The aim of this case review is to highlight the recent advances in understanding the pathogenesis, diagnosis, the overview and the potential renoprotective therapeutic agents that would prevent the development or the progression of diabetic nephropathy.

Downloads

Download data is not yet available.

References

Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017;92(2):388-96.

Allison SJ. Diabetic nephropathy: Glucose metabolic flux in DN. Nat Rev Nephrol 2017;13(7):384.

Axelgaard E, Østergaard JA, Thiel S, Hansen TK. Diabetes is associated with increased autoreactivity of mannan-binding lectin. J Diabetes Res 2017;2017:6368780.

Aoki Y, Tanimoto I, Miyauchi Y, Suzuki Y, Shiojiri T. A case of anti-glomerular basement membrane glomerulonephritis complicated by Type 1 diabetes mellitus, mimicking urinary tract infection. Am J Case Rep 2017;18:308-12.

Begum SM, Hemalatha S. Characterization, in silico and in vitro determination of antidiabetic andanti-inflammatory potential of ethanolic extract of sargassum wighti. Asian J Pharm Clin Res 2017;10(4):297-301.

Haghighatpanah GT, Jha A, Mallayasamy S. Study on prescribing pattern of anti-diabetic drugs among Type 2 diabetes patients with complication in South Indian teaching hospital. Asian J Pharm Clin Res 2016;9 Suppl 1:194-7.

Feigerlová E, Battaglia-Hsu SF. IL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev 2017. pii: S1359-610130030-8.

Haneda M, Utsunomiya K, Koya D, Babazono T, Moriya T, Makino H, et al. A new classification of Diabetic Nephropathy 2014: A report from Joint Committee on Diabetic Nephropathy. J Diabetes Invest 2015;6:242-6.

Amutha A, Anjana RM, Venkatesan U, Ranjani H, Unnikrishnan R, Venkat Narayan KM, et al. Incidence of complications in young-onset diabetes: Comparing Type 2 with Type 1 (the young diab study). Diabetes Res Clin Pract 2017;123:1-8.

Noreen T, Taha M, Imran S, Chigurupati S, Rahim F, Selvaraj M, et al. Synthesis of alpha amylase inhibitors based on privileged indole scaffold. Bioorg Chem 2017;72:248-55.

Al-Waili N, Al-Waili H, Al-Waili T, Salom K. Natural antioxidants in the treatment and prevention of diabetic nephropathy; A potential approach that warrants clinical trials. Redox Rep 2017;22(3):99-118.

Imran S, Taha M, Selvaraj M, Ismail NH, Chigurupati S, Mohammad JI. Synthesis and biological evaluation of indole derivatives as a-amylase inhibitor. Bioorg Chem 2017;73:121-7.

Ahola AJ, Harjutsalo V, Thorn LM, Freese R, Forsblom C, Mäkimattila S, et al. The association between macronutrient intake and the metabolic syndrome and its components in Type 1 diabetes. Br J Nutr 2017;117(3):450-6.

Al Hussain T, Al Mana H, Hussein MH, Akhtar M. Podocyte and parietal epithelial cell interactions in health and disease. Adv Anat Pathol 2017;24(1):24-34.

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017. pii: CJN.11491116.

Bragg F, Holmes MV, Iona A, Guo Y, Du H, Chen Y, et al. Association between diabetes and cause-specific mortality in rural and Urban areas of China. JAMA 2017;317(3):280-9.

Dabelea D, Stafford JM, Mayer-Davis EJ, D’Agostino R Jr, Dolan L, Imperatore G, et al. Association of Type 1 diabetes vs Type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA 2017;317(8):825-35.

Dugbartey GJ. Diabetic nephropathy: A potential savior with rotten-egg†smell. Pharmacol Rep 2017;69(2):331-9.

Hirakawa Y, Tanaka T, Nangaku M. Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. J Diabetes Investig 2017;8(3):261-71.

Homma K, Yoshizawa J, Shiina Y, Ozawa H, Igarashi M, Matsuoka T, et al. A dipeptidyl peptidase-4 inhibitor, teneligliptin, decreases plasma triglyceride-rich lipoprotein remnants in diabetic patients with chronic kidney disease undergoing hemodialysis. Drugs R D 2017.

Irannejad A, Ghajar A, Afarideh M, Khajeh E, Noshad S, Esteghamati S, et al. Association of peripheral nesfatin-1 with early stage diabetic nephropathy. Pathophysiology 2017;24(1):17-22.

Jin L, Wang T, Jiang S, Chen M, Zhang R, Hu C, et al. The association of a genetic variant in SCAF8-CNKSR3 with diabetic kidney disease and diabetic retinopathy in a Chinese population. J Diabetes Res 2017;2017:6542689.

Kemmner S, Lorenz G, Wobst J, Kessler T, Wen M, Günthner R, et al. Dietary nitrate load lowers blood pressure and renal resistive index in patients with chronic kidney disease: A pilot study. Nitric Oxide 2017;64:7-15.

Khidr EG, Ali SS, Elshafey MM, Fawzy OA. Association of irisin and FNDC5 rs16835198 G>T gene polymorphism with Type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study. Gene 2017;626:26-31.

Xing Y, Lai J, Liu X, Zhang N, Ming J, Liu H, et al. Netrin-1 restores cell injury and impaired angiogenesis in vascular endothelial cells upon high glucose by PI3K/AKT-eNOS. J Mol Endocrinol 2017;58:167-77.

Xu Z, Diao Z, Liu R, Liu W. Molecular mechanism of smurf2 in regulating the expression of SnoN in diabetic nephropathy. Mol Med Rep 2017;15(5):2560-6.

Yao M, Gao F, Wang X, Shi Y, Liu S, Duan H. Nox4 is involved in high glucose-induced apoptosis in renal tubular epithelial cells via Notch pathway. Mol Med Rep 2017;15(6):4319-25.

Zhang H, Nair V, Saha J, Atkins KB, Hodgin JB, Saunders TL, et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. Kidney Int 2017. pii: S0085-253830230-2.

Zanchi C, Macconi D, Trionfini P, Tomasoni S, Rottoli D, Locatelli M, et al. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. Diabetologia 2017;60(6):1114-25.

Yuan CM, Nee R, Ceckowski KA, Knight KR, Abbott KC. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin Kidney J 2017;10(2):257-62.

Zha D, Wu X, Gao P. Adiponectin and its receptors in diabetic kidney disease: Molecular mechanisms and clinical potential. Endocrinology 2017.

Yokoi H, Mukoyama M. Analysis of pathological activities of CCN proteins in fibrotic diseases: Kidney fibrosis. Methods Mol Biol 2017;1489:431-43.

Xu L, Niu M, Yu W, Xia W, Gong F, Wang O. Associations between FGF21, osteonectin and bone turnover markers in Type 2 diabetic patients with albuminuria. J Diabetes Complications 2017;31(3):583-8.

Xue R, Gui D, Zheng L, Zhai R, Wang F, Wang N. Mechanistic insight and management of diabetic nephropathy: Recent progress and future perspective. J Diabetes Res 2017;2017:1839809.

Yang S, Han Y, Liu J, Song P, Xu X, Zhao L, et al. Mitochondria: A novel therapeutic target in diabetic nephropathy. Curr Med Chem 2017.

Vitova L, Tuma Z, Moravec J, Kvapil M, Matejovic M, Mares J, et al. Early urinary biomarkers of diabetic nephropathy in Type 1 diabetes mellitus show involvement of kallikrein-kinin system. BMC Nephrol 2017;18(1):112.

Wanner N, Bechtel-Walz W. Epigenetics of kidney disease. Cell Tissue Res 2017;369(1):75-92.

Wasik AA, Dumont V, Tienari J, Nyman TA, Fogarty CL, Forsblom C, et al. Septin 7 reduces nonmuscle myosin IIA activity in the SNAP23 complex and hinders GLUT4 storage vesicle docking and fusion. Exp Cell Res 2017;350(2):336-48.

Wimalasena S, Kendrick-Jones J, Hawkins S, Talreja H. Renal artery embolisation for uncontrolled hypertension in ESRD. N Z Med J 2017;130(1448):73-6.

Published

01-11-2017

How to Cite

Islam Mohammad, J., S. Chigurupati, A. S. Othman, and M. Zahid Iqbal. “DIABETIC NEPHROPATHY AN OBVIOUS COMPLICATION IN LONG TERM TYPE 1 DIABETES MELLITUS: A CASE STUDY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 11, Nov. 2017, pp. 4-7, doi:10.22159/ajpcr.2017.v10i11.20699.

Issue

Section

Case Study(s)

Most read articles by the same author(s)